ENHANCED MALIGNANT CONVERSION OF BENIGN MOUSE SKIN TUMORS BY CISPLATIN

被引:30
作者
HENNINGS, H
SHORES, RA
POIRIER, MC
REED, E
TARONE, RE
YUSPA, SH
机构
[1] NCI,CELLULAR CARCINOGENESIS & TUMOR PROMOT LAB,BETHESDA,MD 20205
[2] NCI,CLIN ONCOL PROGRAM,BETHESDA,MD 20205
[3] NCI,BIOSTAT BRANCH,BETHESDA,MD 20205
关键词
D O I
10.1093/jnci/82.10.836
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The chemotherapeutic agent cisplatin, reported to be a complete carcinogen in rodents and a tumor initiator for mouse skin, was tested for activity to enhance the conversion of carcinogen-induced skin papillomas to carcinomas. Initiation of mouse skin by 7,12-dimethylbenz[a]anthracene followed by 12 weeks of promotion by 12-O-tetradecanoylphorbol-13-acetate produced seven to eight papillomas/mouse. Ten weekly injections of 100 μg of cisplatin into these papilloma-bearing mice induced a 2.3-fold enhancement of conversion relative to the spontaneous rate of 1.9%. Even a single exposure to cisplatin in tumor-bearing mice increased the carcinoma incidence to the same extent as 10 exposures to urethane, an agent previously shown to enhance malignant conversion. At the dose tested, cisplatin was inactive as a complete carcinogen or a tumor promoter. Cisplatin-DNA adducts, measured in samples from skin, liver, and kidneys, were persistent for at least 4 weeks after the last exposure to cisplatin. Thus cisplatin is a relatively potent inducer of the putative genotoxic changes required for conversion of skin tumors from a benign to a malignant phenotype. The activity of cisplatin in the initiation and malignant conversion stages in this animal model for carcinogenesis suggests that patients given cisplatin-based chemotherapy are at increased risk for the development of treatment-induced second cancers. [J Natl Cancer Inst 82:836-840, 1990] © 1990 Oxford University Press.
引用
收藏
页码:836 / 840
页数:5
相关论文
共 23 条
[1]   CISPLATIN AS AN INITIATING AGENT IN 2-STAGE MOUSE SKIN CARCINOGENESIS [J].
BARNHART, KM ;
BOWDEN, GT .
CANCER LETTERS, 1985, 29 (01) :101-105
[2]  
BASSETT WB, 1986, J CLIN ONCOL, V4, P614
[3]   SEQUENCE SPECIFICITY OF MUTATION INDUCED BY THE ANTI-TUMOR DRUG CISPLATIN IN THE CHO APRT GENE [J].
DEBOER, JG ;
GLICKMAN, BW .
CARCINOGENESIS, 1989, 10 (08) :1363-1367
[4]  
Gart J J, 1986, IARC Sci Publ, P1
[5]   MALIGNANT CONVERSION OF MURINE SQUAMOUS PAPILLOMA CELL-LINES BY TRANSFECTION WITH THE FOS ONCOGENE [J].
GREENHALGH, DA ;
YUSPA, SH .
MOLECULAR CARCINOGENESIS, 1988, 1 (02) :134-143
[6]   SPONTANEOUS HA-RAS GENE ACTIVATION IN CULTURED PRIMARY MURINE KERATINOCYTES - CONSEQUENCES OF HA-RAS GENE ACTIVATION IN MALIGNANT CONVERSION AND MALIGNANT PROGRESSION [J].
GREENHALGH, DA ;
WELTY, DJ ;
STRICKLAND, JE ;
YUSPA, SH .
MOLECULAR CARCINOGENESIS, 1989, 2 (04) :199-207
[7]   MALIGNANT CONVERSION AND METASTASIS OF MOUSE SKIN TUMORS - A COMPARISON OF SENCAR AND CD-1 MICE [J].
HENNINGS, H ;
SPANGLER, EF ;
SHORES, R ;
MITCHELL, P ;
DEVOR, D ;
SHAMSUDDIN, AKM ;
ELGJO, KM ;
YUSPA, SH .
ENVIRONMENTAL HEALTH PERSPECTIVES, 1986, 68 :69-74
[8]  
HENNINGS H, 1983, NATURE, V304, P67, DOI 10.1038/304067a0
[9]   2ND MALIGNANCIES FOLLOWING TESTICULAR CANCER, OVARIAN-CANCER AND HODGKINS-DISEASE - AN INTERNATIONAL COLLABORATIVE STUDY AMONG CANCER REGISTRIES [J].
KALDOR, JM ;
DAY, NE ;
BAND, P ;
CHOI, NW ;
CLARKE, EA ;
COLEMAN, MP ;
HAKAMA, M ;
KOCH, M ;
LANGMARK, F ;
NEAL, FE ;
PETTERSSON, F ;
POMPEKIRN, V ;
PRIOR, P ;
STORM, HH .
INTERNATIONAL JOURNAL OF CANCER, 1987, 39 (05) :571-585
[10]  
KALDOR JM, 1986, IARC SCI PUBL, V70, P327